October 4, 2026

A treatment can look promising on a screen and still be difficult to use on a Tuesday night.

That is the question behind a September study protocol from researchers working across five Veterans Affairs sites. They are comparing two levels of support alongside digital cognitive behavioral therapy for insomnia, or digital CBT-I. The trial will examine sleep symptoms, mental health symptoms, engagement, and how the service fits into clinical care.

The crucial word is protocol. This paper describes the study's design. It does not report that coaching improved sleep.

Even without results, the question deserves attention. Making a program available and making it usable are different jobs. A download button cannot answer a question, notice confusion, or help someone return after a difficult week. It does, however, remain impressively confident about its own loading circle.

Read the September 12 protocol.

The VA study enrolls veterans referred by health care providers and screens for reasons digital CBT-I might be unsuitable. It compares adjunctive support, rather than treating every insomnia app as interchangeable.

That distinction matters. Evidence about a particular clinical program cannot automatically validate a consumer product with a soothing color palette. The paper's abstract does not report a completed sample size or treatment effects. We will need the results before judging this coaching approach.

A separate September 1 paper explored older adults' responses to information about sleeping medications and CBT-I at two VA facilities. This was a qualitative analysis within a pilot randomized trial. Of 120 people assigned to a brochure plus telephone reinforcement arm, 72 completed a call.

Researchers found varied recall of the brochure, varied plans to discuss medication use or try digital CBT-I, and different beliefs about long-term medication use. Digital access barriers also featured in the conclusions.

These interviews help explain engagement. They do not show that the brochure safely reduced medication use or that the findings represent every older adult. Participation in the calls may also shape whose views were captured.

Read the participant-perspectives study.

The two September papers put an ordinary practical problem back into the sleep conversation: what happens between receiving information and acting on it?

One paper sets out to test support. The other listens to people who received a low-touch intervention. They are different kinds of evidence, and neither supplies a universal solution.

Our editorial reading is that access deserves more careful questions. Is a service simply offered, or can people understand and use it? Is there a place to ask questions? What happens when internet access, confidence with technology, or the demands of daily life get in the way?

Those are questions about service design, not a diagnosis of anyone's motivation.

There is also a measurement question. An app installation is easy to count. A completed program is different. A change in insomnia severity is different again. Research should help us distinguish them before a marketing department turns all three into the same cheerful chart.

The forthcoming coaching results could inform one part of that discussion. Until then, the appropriate conclusion is modest: researchers are testing how to integrate support with digital insomnia care. They have not yet established the answer in this paper.

For readers, a useful question about any sleep-treatment headline is: what exactly was tested, with what support, and in whom? The details belong in the headline conversation, even when they refuse to fit neatly on a phone screen.

An earlier randomized crossover trial offers a reason to be careful with that conclusion. Published online in 2024 and in a 2025 issue of Sleep, it tested single 100-mg and 400-mg caffeine doses at 12, eight, and four hours before bed in 23 young men with moderate habitual caffeine intake.

The 100-mg conditions did not significantly differ from placebo on the measured sleep outcomes. The 400-mg conditions affected objective sleep, including when taken well before bedtime. Participants' perceived sleep quality did not consistently reflect the objectively measured changes.

This is a small, specific sample. A statistically nonsignificant result does not establish that 100 mg is harmless for everyone. Nor does the trial create a personal cutoff for women, older adults, people with insomnia, or people taking medications.

The narrow lesson: feeling unaffected is not a perfect measurement tool. A confident morning opinion is still an opinion.

Read the caffeine trial.

Sleep care does not end when instructions are handed over.

The participant-perspectives paper is a reminder to ask people what they understood and what they can realistically use. The coaching protocol asks whether a more supported digital service can work better in practice. These are pieces of a care-delivery question, not instructions to start, stop, or taper a medication.

Medication decisions require a qualified clinician. This newsletter cannot turn a study into an individual treatment plan.

This week, try one question when a sleep headline arrives: Is this a result, a plan to test something, or an explanation of people's experiences?

All three can be useful. They answer different questions.

Know someone tired of miracle sleep headlines? Forward this issue. They can find The Sleep News and its free weekly subscription at thesleepnews.com.

1. Ulmer and colleagues. Coach supported digital cognitive behavioral therapy for insomnia: protocol for a randomized controlled trial. Contemporary Clinical Trials. Online September 12, 2026. PubMed and DOI. DOI.
2. Mak and colleagues. Eliciting participant perspectives about a mailed brochure on sleeping pills and cognitive behavioural therapy for insomnia to inform future implementation of deprescribing interventions. International Journal of Pharmacy Practice. Online September 1, 2026. PubMed. DOI.
3. Gardiner and colleagues. Dose and timing effects of caffeine on subsequent sleep: a randomized clinical crossover trial. Sleep. 2025;48(4):zsae230; online 2024. PubMed. DOI.

Medical disclaimer: The Sleep News provides general information, not personal medical advice. Insomnia, sleep apnea, medication questions, breathing problems during sleep, and child or adult health concerns should be discussed with a qualified clinician.